Alzheimer'
Conditions
Interventions
None listed
Sponsors
Nihon University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients of the Nihon University hospital, that were prescribed anti-Alzheimer drugs memantine hydrochloride, donepezil hydrochloride, galantamine hydrobromide or rivastigmine, between January 1, 2010 and September 30, 2016. (1) Patients with medical records during the research period (January 1, 2010 - September 30, 2016) (2) Patients to whom memantine hydrochloride, donepezil hydrochloride, galantamine hydrobromide or rivastigmine is prescribed. (3) Patients who are 60 years of age or older at the time of "initial prescription" where initial prescription" is defined as the earliest prescription of one of the said Alzheimer drugs 52 or more weeks after the eligibility judgement date earlier day with a medical record within the research period.
Exclusion criteria
Exclusion criteria: (1) Patients without a medical record between one day and 52 weeks before the date of initial prescription. (2) Patients whose initial prescription day is October 1, 2015 or later. (3) Patient who were prescribed an Anti-Alzheimer drug of the identical active ingredient between the day before to 52 weeks before the initial prescription date. (4) Lewy body type dementia patients. (5) Patients to whom memantine hydrochloride and cholinesterase inhibitor were initially prescribed on the same day. (6) Patients with PDC (proportion of days covered i.e. percentage of days prescribed during the survey period) less than 80%.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Temporal change in the percentage of patients to which psychotropic drugs (antipsychotic, antidepressant, antianxiety and hypnotic drugs) are prescribed from 52 weeks before the start of prescription to the day before the prescription of memantine hydrochloride start date, and from the start of prescription of memantine hydrochloride to 52 weeks after or end of exposure. | — |
Secondary
| Measure | Time frame |
|---|---|
| Temporal change in the percentage of patients to which psychotropic drugs (antipsychotic, antidepressant, antianxiety and hypnotic drugs) are prescribed from 52 weeks before the start of prescription to the day before the prescription of cholinesterase inhibitor start date, and from the start of prescription of cholinesterase inhibitor to 52 weeks after or end of exposure. | — |
Countries
Japan
Contacts
Public ContactSatoshi Asai
Nihon University Medical Faculty Clinical Trial Center
Outcome results
None listed